The web site logo

The pharmacologic management of non-HDL-C and its goal attainment, demands consideration of not only selective utilization of combinations of lipid-modifying agents (bile acid sequestrants, ezetimibe, fibrates, omega-3 ethyl esters, niacin, with statins), but also the pharmacologic optimization of co-morbidities, e.g. nephropathy (albuminuria) and glycemic control of diabetes, as well as, evaluation of medicinal agents, that might contribute to elevated non-HDL-C, all against the background of aggressive therapeutic lifestyle recommendations that potentially minimize pharmaceutical requirements.